COMPANY PROFILE

Biovantic is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. Biovantic product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars, brands and OTC products.

We understand that trust and reliability are vital requirements for today’s fast-paced generics environment and fulfil these demands with a friendly, professional customer service team.

OUR PORFOLIO

Our portfolio of products spans a range of channels and therapeutic areas

Central Nervous System
Gastroenterology
Anti-Diabetic
Anti-Histamines
Respiratory
Ophthalmology
Ear Care
Intimate Care Products
Dental Care

WHAT WE DO

Biovantic Pharma is a rapidly expanding pharmaceutical and medical device manufacturer based in the United Kingdom. Biovantic Pharma is ethically committed to providing competent and unbiased product advice. Our company has strong relationships with a number of local and international pharmaceutical distributors, manufacturers, and full-service wholesalers.

WHY CHOOSE US?

We specialise in bringing to market a variety of premium, reasonably priced solutions that address the demands of contemporary healthcare delivery. By offering a top-notch service in a quick and dependable manner, we make it possible for everyone to have access to medicines, wherever they may be in the world. In all aspects of our business, we promote innovation and originality in order to exceed customer expectations.

LEADING DISTRIBUTOR

Biovantic Pharma is a leading distributor and wholesaler of pharmaceutical, medical, healthcare products and API globally. Based in London (UK), we offer a high level of service and provide a full complement of added value services to pharmacies, retailers, organizations, hospitals, charities, distributors globally.